Ms. Allen has served as a member of the Board of Directors of Deciphera Pharmaceuticals and as the Chairperson of the Audit Committee since September 2016.  Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. Ms. Allen is currently the Chief Financial Officer of Vividion Therapeutics, Inc. since March 2021. From January 2013 to May 2020, Ms. Allen served as Chief Financial Officer of Zafgen, Inc., now Larimar Therapeutics Inc. From 2011 to 2012, Ms. Allen provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations, and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. She currently serves on the Board of Directors of Yumanity Therapeutics, Inc..  Ms. Allen graduated summa cum laude from Bryant College with a B.S. in Business Administration.